Country: Canada
Language: English
Source: Health Canada
IPRATROPIUM BROMIDE
PHARMASCIENCE INC
R03BB01
IPRATROPIUM BROMIDE
250MCG
SOLUTION
IPRATROPIUM BROMIDE 250MCG
INHALATION
1ML
Prescription
ANTIMUSCARINICS ANTISPASMODICS
Active ingredient group (AIG) number: 0115643001; AHFS:
APPROVED
1997-04-25
_pms-IPRATROPIUM Product Monograph Page 1 of 28_ PRODUCT MONOGRAPH PR PMS-IPRATROPIUM Ipratropium Bromide Inhalation Solution 125 mcg/mL & 250 mcg/mL BRONCHODILATOR PHARMASCIENCE INC. 6111 Royalmount Avenue, Suite 100 Montreal, Quebec H4P 2T4 www.pharmascience.com Date of Revision: April 12, 2017 Control No: 197460 _pms-IPRATROPIUM Product Monograph Page 2 of 28_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................3 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ....................................................................................................9 DOSAGE AND ADMINISTRATION ..............................................................................10 OVERDOSAGE ................................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY ............................................................11 STORAGE AND STABILITY ..........................................................................................14 SPECIAL HANDLING INSDTUCTIONS .......................................................................14 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................14 PART II: SCIENTIFIC INFORMATION ...............................................................................16 PHARMACEUTICAL INFORMATION ..........................................................................16 CLINICAL TRIALS ................ Read the complete document